Antitumor diarylsulfonylureas: Novel agents with unfulfilled promise

Peter J. Houghton, Janet A. Houghton

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Diarylsulfonylureas represent a class of antitumor agent with significant therapeutic efficacy against rodent and human models of cancer. Despite the exciting preclinical activity of sulofenur, the prototypic agent, clinical activity was poor. Here we review the activity of sulofenur and a second generation diarylsulfonylurea, LY295501 N-[5-(2,3-dihydrobenzofuryl) sulfonyl]-N'-(3,4-dichlorophenyl)urea, against colon tumor xenografts, and some of the cellular pharmacology of this class of antitumor agents.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalInvestigational New Drugs
Volume14
Issue number3
DOIs
StatePublished - 1996
Externally publishedYes

Keywords

  • Diarylsulfonylureas
  • Pharmacology
  • Xenografts

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Antitumor diarylsulfonylureas: Novel agents with unfulfilled promise'. Together they form a unique fingerprint.

Cite this